| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +19.1K | +31.36% | $0.00 | 80.1K | Feb 13, 2025 | Direct | F1 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +7.84K | +9.79% | $0.00 | 87.9K | Feb 13, 2025 | Direct | F2 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +9.27K | +10.54% | $0.00 | 97.2K | Feb 13, 2025 | Direct | F3 |
| transaction | ABBV | Common Stock, $0.01 par value | Award | $0 | +9.43K | +9.71% | $0.00 | 107K | Feb 13, 2025 | Direct | F4 |
| holding | ABBV | Common Stock, $0.01 par value | 1.34K | Feb 13, 2025 | By spouse in trust | F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Option (Right to Buy) | Award | $0 | +33.9K | $0.00 | 33.9K | Feb 13, 2025 | Common Stock | 33.9K | $192.86 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F2 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F3 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F4 | Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025. |
| F5 | The reporting person disclaims beneficial ownership of all securities held by his spouse. |
| F6 | Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,285 on February 13, 2026, 11,285 on February 13, 2027, and 11,284 on February 13, 2028. |
Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 in Table II Column 2, instead of the correct value of $175.28